Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 |
| clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 | 40 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695896 | Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | not yet recruiting | — | 200 | Yanyan LiuOTHER_GOV | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07690891 | Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07691034 | Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry | not yet recruiting | — | 40 | Odense University HospitalOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07684274 | Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | not yet recruiting | — | 290 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | not yet recruiting | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682415 | Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0(ZS) | not yet recruiting | Phase 2 | 60 | Yi ShuhuaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 25 | Jennifer WoyachOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | Luminary TherapeuticsINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674810 | A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07676877 | Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | not yet recruiting | Phase 1 | 18 | Nathan DenlingerOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07671287 | GMMG-HD11/DSMM XXI/64007957MMY3010(AugMMent) | not yet recruiting | Phase 3 | 399 | University of Heidelberg Medical CenterOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07669194 | Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma(Glofit-Sel) | not yet recruiting | — | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07614360 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM-16) | not yet recruiting | Phase 2 | 150 | GlaxoSmithKlineINDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07664787 | Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study(STAR) | not yet recruiting | N/A | 20 | Ruijin HospitalOTHER | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07247097 | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma(ELDORADO) | not yet recruiting | Phase 2 | 160 | Massachusetts General HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07376330 | Molecular and Cellular Characterization of MALT Lymphoma | not yet recruiting | — | 400 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07592481 | Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors(HEMO-CONNECT) | not yet recruiting | N/A | 40 | Centre Hospitalier de la côte BasqueOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07652476 | Neurocognitive Assessment in Long-Term Survivors of Lymphoma(FIL_LymDeCo) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658352 | A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 114 | Shanghai Helioson Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07654465 | Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma(ROMA) | not yet recruiting | Phase 2 | 144 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma(BELAMI) | not yet recruiting | Phase 1 / Phase 2 | 44 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07646873 | PET-Enabled Dual-Energy CT in Multiple Myeloma | not yet recruiting | N/A | 45 | University of California, DavisOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647432 | HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV(HEME-25) | not yet recruiting | Phase 2 / Phase 3 | 17 | University of Illinois at ChicagoOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07220187 | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial | not yet recruiting | Phase 3 | 102 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07335328 | Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies | not yet recruiting | Phase 1 | 24 | Medical College of WisconsinOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 19 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07637929 | Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | not yet recruiting | — | 200 | Chongqing Precision Biotech Co., LtdINDUSTRY | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07638982 | Axatilimab + CAR-T for High-Risk Lymphoma | not yet recruiting | Phase 1 | 29 | Northside Hospital, Inc.OTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment | not yet recruiting | Phase 2 | 90 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07191379 | Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma(SCILLA) | not yet recruiting | Phase 4 | 50 | Odense University HospitalOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07614022 | A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) | not yet recruiting | Phase 1 | 26 | Wake Forest University Health SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07622784 | Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma | not yet recruiting | Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623655 | CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia | not yet recruiting | — | 107 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07624760 | Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging(MGUS-PET) | not yet recruiting | N/A | 50 | University of ZurichOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624799 | Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).(PACIFIC) | not yet recruiting | Phase 2 | 82 | French Innovative Leukemia OrganisationOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors(FXS0683-001) | not yet recruiting | Phase 1 | 228 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07611149 | Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma | not yet recruiting | Phase 1 | 12 | Kure Cells, INCINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT07609355 | AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma(GLORIA) | not yet recruiting | N/A | 25 | Sun Yat-sen UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609446 | Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | not yet recruiting | — | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | not yet recruiting | Phase 1 | 20 | GlaxoSmithKlineINDUSTRY | 0 | May 27, 2026 | clinicaltrials |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma(CONQUISTADOR) | not yet recruiting | Phase 1 / Phase 2 | 220 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07593482 | Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.(FC-BALANCE) | not yet recruiting | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 15, 2026source: clinicaltrials